It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Make confident translational decisions with integrated PK and PK/PD modelling that connects high-quality in vitro and in vivo data to predictive simulations. We help you optimize dose selection, refine study design, and anticipate human exposure-response early reducing attrition and accelerating progression from hit-to-lead through IND-enabling studies and beyond.
Our integrated approach combines in vitro screening data, in vivo pharmacology, and computational modelling to optimize dose selection, study design, and progression strategies, reducing attrition and accelerating development timelines.
Through simulation-based approaches, we translate in vitro potency, selectivity, and safety data into actionable dosing recommendations for pharmacodynamic studies. These models predict exposure–response relationships, identify potential liabilities early, and de-risk compound progression into in vivo studies. Our PK/PD modelling establishes quantitative concentration–effect relationships, enabling the translation of preclinical data into clinically relevant exposure profiles and effective human dosing regimens. This approach supports rational decision-making in candidate selection, formulation development, and clinical trial design.
Physiologically Based Pharmacokinetic (PBPK) Modelling
PBPK modelling integrates physiological parameters, drug-specific properties, and mechanistic ADME knowledge to simulate human pharmacokinetics. These models support in vitro–in vivo extrapolation (IVIVE), prediction of systemic exposure, and first-in-human dose projections, providing a strong simulation-supported rationale for regulatory interactions and clinical planning. Our approach also evaluates drug-drug interaction risk early by simulating a compound’s impact on metabolic enzymes, such as CYPs and UGTs, and transporters, such as P-gp and BCRP. These insights help forecast clinical safety issues and strengthen regulatory submissions.
Strategic Modelling for Due Diligence
Our modelling and simulation services support strategic decision-making during in-licensing and out-licensing activities. Mechanistic analysis, PBPK modelling, and PK/PD simulations help assess compound viability and inform investment decisions with scientific rigor. This integrated modelling framework enables confident, data-driven decisions across discovery and development, supports translational success and reduces risk in early-stage drug development.
Why Choose Sygnature Discovery for Biotransformation Support?
Sygnature Discovery combines deep scientific expertise with advanced computational capabilities to deliver predictive modelling and simulation solutions that inform decision-making across drug discovery and development. Our strategies integrate in vitro and in vivo data with tools such as PBPK modelling, allometric scaling, and mechanistic simulations to ensure translational relevance. We specialize in:
Translating in vivo data into actionable PK/PD insights for rational dose selection and therapeutic index estimation.
Optimizing dosing strategies through PBPK and allometric modelling for reliable human extrapolation.
Predicting human pharmacokinetics using mechanistic simulations that inform study design and clinical development planning.
Evaluating drug–drug interaction risks to guide regulatory strategy and submission readiness.
Strengthening due diligence with robust, data-driven analysis that supports candidate selection and investment decisions.
By embedding modelling and simulation within an integrated discovery framework, we reduce development risk, enable translational success and accelerate progression to the clinic.
Bifunctional degraders bind and degrade proteins via ubiquitin ligase, despite breaking bRo5 rules. Translating in vitro DMPK data to in vivo performance remains a challenge. At Sygnature Discovery, we provide tailored assays and expertise to support projects involving these compounds. Read more in the poster.
Modelling and simulation approaches developed under the DMPK umbrella utilising animal in vivo data and…
Blog
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated solid form and formulation strategies reduce risk, improve stability and solubility, and accelerate progression from candidate selection to clinic.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
